Sapropterin dihydrochloride (6r-bh4) (DrugBank: Sapropterin, 6R-BH4)
5 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
51 | Scleroderma | 0 |
86 | Pulmonary arterial hypertension | 1 |
124 | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy | 0 |
240 | Phenylketonuria | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00435331 (ClinicalTrials.gov) | March 2008 | 12/2/2007 | 6R-BH4 Pulmonary Arterial Hypertension Study | A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of 6R-BH4 in Subjects With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: sapropterin dihydrochloride (6R-BH4) | Vanderbilt University | National Institutes of Health (NIH);BioMarin Pharmaceutical | Completed | 18 Years | N/A | Both | 14 | Phase 1 | United States |